STC2 and atherosclerosis: Subsequent pre-clinical studies have established proof-of-principle for inhibiting the proteolytic activity of PAPP-A in atherosclerosis either using recombinant STC2 [16] or an antibody specifically targeting the LNR domain of PAPP-A30.